Become an IMR Panelist
IMR Logo

Neutralizing Antibody Market Size, Share & Forecast (2024-2032)

Neutralizing Antibody Market By Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Target Virus (SARS-CoV-2 (COVID-19), HIV, Influenza, Ebola, Zika, Hepatitis C, Others), Application (Therapeutics, Diagnostics, Research and Development), End User (Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies ,Others), Distribution Channel (Direct Sales to End-Users, Distributors, Online Retail, Others) and Region

  • Report ID : 20805
  • Category : Biotechnology
  • Format :Excel formatPDF formatWord format
Request Sample

Neutralizing Antibody Market Synopsis:

Neutralizing Antibody Market Size Was Valued at USD 191 Billion in 2023, and is Projected to Reach USD 338.98 Billion by 2032, Growing at a CAGR of 9% From 2024-2032.

The Neutralizing Antibody Market deals with the production and market of the antibodies that counter the action of pathogenic organisms including viruses and bacteria. They are critical in regulating immune response because they prevent the viruses and bacteria from entering the host cells making then imperative in treatment of diseases, auto immune diseases and also cancer. The market has begun growing in the recent past, especially with developments in improved biotechnological approaches that facilitate the discovery and production of reagents, which neutralize new pathogens including the SARS-CoV-2 virus.

Major growth stimulants behind the Neutralizing Antibody Market include rising incidence of infectious illnesses, innovation and development activities and enhanced requirement for precise treatments. The COVID-19 crisis specifically has driven interest in neutralizing antibodies, readily spurring the development of monoclonal antibody and antiviral therapies. Moreover, pharma and biotech alliances and partnerships with academic and research institutions are propelling the growth of novel and innovative antibody discovery and development and expanding the therapeutic armamentarium.

However, the market also has problems like huge research and development costs, long procedural legal requirements, and strenuous trials including efficacy and safety. Nevertheless, there are a lot of opportunities in the market with the development of genetic engineering and medicine on the individual basis. The rising interest in biotechnology and indeed the growing use of neutralizing antibodies across multiple therapeutic segments is evidence of growth opportunities for the Neutralizing Antibody Market in the future.

Neutralizing Antibody Market

Neutralizing Antibody Market Trend Analysis:

Surge in Monoclonal Antibody Development

  • The mAbs is another major trend in the market studied wherein the market is likely to witness enhanced adoption of targeted Neutralizing Antibodies in the treatment of diseases in the coming years. This trend has been particularly affected by the COVID-19 pandemic as pushed the development of neutralizing mAbs against to limit the severity of the illness. Biopharmaceutical firms have shifted towards mAb platforms to develop a selective and potent reagent that can selectively and with high affinity interact with pathogens making it a nod for treatment of various infectious diseases, both systemic as well as autoimmune diseases and some types of cancers. Hybridoma technology and phage display are now coming into use for the identification and optimization of these antibodies and this is stimulating the market growth of this segment.

Expansion of Combination Therapies

  • Another trend is the increasing use of combination therapies where neutralizing antibodies also act as a component of combination with vaccines and small molecule drugs. This approach is for improving the outcome of the treatments and for offering a more holistic solution on the fight against diseases; canker, cancer and viral diseases inclusive. Such integrated therapies harmonize the activity of neutralizing antibodies with other therapies making them more effective in dealing with patients’ needs, minimizing the development of resistance, and targeting various patient populations at the same time. Further, ongoing clinical trials related to the combinations strengthen this kind of approach in the Neutralizing Antibody Market.

Neutralizing Antibody Market Segment Analysis:

Neutralizing Antibody Market is Segmented on the basis of Antibody Type, Target Virus, Application, End User, Distribution Channel, and Region.

By Antibody Type, Monoclonal Antibodies segment is expected to dominate the market during the forecast period

  • There are four global segments for Neutralizing Antibody Market depending on antibody type: Monoclonal antibodies (mAbs) and Polyclonal antibodies (pAbs) having their advantages while using in therapeutic areas. Monoclonal antibodies are designed to fit well on target antigens, therefore, they are used to treat many diseases such as cancers and viral infections diseases. Because of their mass production and the ability to alter their effectiveness, their usage has spiked, especially in reference to new viral ailments. By contrast, poly/ectsclonal antibodies are several antibodies that can target one single epitome and several other epitome on the same antigen for enhanced immune response. They are routinely employed in circumstances, for instance passive immunization therapy, where quick effect is most desirable. Technological innovations in the fields of antibody engineering and production are anticipated to add value and versatility to the utilisation of both monoclonal and polyclonal antibodies in the neutralizing antibody arena.

By Application, Diagnostics segment expected to held the largest share

  • Market segmentation for the neutralizing antibody market is done on the basis of application which includes therapeutics, diagnostics, and research and development (R&D). Neutralizing antibodies are effectively being used in therapeutics as targeted therapies for numerous diseases, viral, autoimmune diseases, and even cancer, which give ahead for patient-specific medication. In diagnostics, these antibodies are of great help in determining which particular pathogen is present in the body and as early as possible. The R & D segment centers on identification and description of new uses of neutralizing antibodies to encourage novel vaccines and other therapeutic approaches. This diverse application picture underlines the versatile use and increasing importance of antagonising antibodies in every area of medicine, which again underlines their importance for the further development of medical science and for patients.

Neutralizing Antibody Market Regional Insights:

North America is the largest market for neutralizing antibodies, accounting for a market share

  • The study found out that North American region had the highest market share for neutralizing antibodies due to the region’s advanced health care system, research activities and well established drug manufacturing industries.. The US and Canada have been pioneers of immunotherapy and biotechnology, embracing and propagating the technology and launching of neutralizing antibodies for various diseases, including viral infections, cancer and autoimmunity. Furthermore, the government provides significant funding for the region, favourable regulations and high healthcare technology investment reinforces the market for neutralizing antibody in the region. The COVID-19 pandemic has also lent a sense of urgency to research and the commercial application of monoclonal antibody therapies, and so has cemented North America’s position in the fast-growing market.

Active Key Players in the Neutralizing Antibody Market:

  • Regeneron Pharmaceuticals, Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • AstraZeneca PLC (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • Sanofi SA (France)
  • Roche Holding AG (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Johnson & Johnson (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Moderna, Inc. (U.S.)
  • BioNTech SE (Germany)
  • CSL Limited (Australia)
  • Sinovac Biotech Ltd. (China)
  • Other Active Players

Global Botanical Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 191 Billion

Forecast Period 2024-32 CAGR:

 9%

Market Size in 2032:

USD 338.98  Billion

Segments Covered:

By Antibody Type
  • Monoclonal Antibodies
  •  Polyclonal Antibodies

By Target Virus
  • SARS-CoV-2 (COVID-19)
  •  HIV
  • Influenza
  • Ebola
  • Zika
  • Hepatitis C
  • Others

By Application
  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical Companies
  • Others

By End User
  • Hospitals and Clinics,
  • Research Institutes,
  • Diagnostic Laboratories,
  • Pharmaceutical Companies
  • Others

By Distribution Channel
  • Direct Sales to End-Users
  • Distributors
  • Online Retail
  • Others

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • The increasing prevalence of infectious diseases and the rising demand for targeted therapies are driving growth in the Neutralizing Antibody Market.

Key Market Restraints:
  • High research and development costs, along with stringent regulatory requirements, pose significant challenges to market expansion.

Key Opportunities:
  • The advancement of biotechnological innovations and the growing interest in personalized medicine present substantial opportunities for the development of novel neutralizing antibodies.

Companies Covered in the report:
  • Regeneron Pharmaceuticals, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca PLC (U.K.), GlaxoSmithKline plc (U.K.), Sanofi SA (France), Roche Holding AG (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Moderna, Inc. (U.S.), BioNTech SE (Germany), CSL Limited (Australia), Sinovac Biotech Ltd. (China), and Other Active Players

 

Frequently Asked Questions :

What would be the forecast period in the Neutralizing Antibody Market research report?
The forecast period in the Neutralizing Antibody Market research report is 2024-2032.
Who are the key players in the Neutralizing Antibody Market?
Regeneron Pharmaceuticals, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca PLC (U.K.), GlaxoSmithKline plc (U.K.), Sanofi SA (France), Roche Holding AG (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Moderna, Inc. (U.S.), BioNTech SE (Germany), CSL Limited (Australia), Sinovac Biotech Ltd. (China), and Other Active Players
What are the segments of the Neutralizing Antibody Market?
The Neutralizing Antibody Market is segmented into By Antibody Type, By Target, By Application, End User, By Distribution Channel, and region. By Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), By Target Virus (SARS-CoV-2 (COVID-19), HIV, Influenza, Ebola, Zika, Hepatitis C, Others), By Application (Therapeutics, Diagnostics, Research and Development), By End User (Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, Others), By Distribution Channel (Direct Sales to End-Users, Distributors, Online Retail, Others). By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Neutralizing Antibody Market?
Neutralizing antibodies are a specific type of antibody that can bind to pathogens, such as viruses and bacteria, and inhibit their ability to infect host cells. These antibodies play a crucial role in the immune response by preventing pathogens from entering cells, thereby neutralizing their harmful effects. Neutralizing antibodies are produced by the immune system in response to an infection or vaccination, and their presence can indicate a protective immune response. They are also the focus of therapeutic development, particularly in the context of infectious diseases and cancer, as they can be engineered or isolated for use in treatments aimed at enhancing immune protection or directly targeting disease-causing agents. The effectiveness of neutralizing antibodies is a key factor in vaccine efficacy and therapeutic interventions.
How big is the Neutralizing Antibody Market?
Neutralizing Antibody Market Size Was Valued at USD 191 Billion in 2023, and is Projected to Reach USD 338.98 Billion by 2032, Growing at a CAGR of 9% From 2024-2032.
Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.